NCT04237480 is a clinical trial of serum value 1,25(OH)2 vitamin D in Hydroxylase Deficiency, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT04237480?

NCT04237480 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT04237480?

Interventions in NCT04237480: serum value 1,25(OH)2 vitamin D.

What condition does NCT04237480 study?

NCT04237480 studies Hydroxylase Deficiency.

Is NCT04237480 still recruiting?

NCT04237480 is currently completed. Last updated 11 February 2020.

Last reviewed 2020-02-11 · How we verify

NCT04237480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of Kidney Performance and Magnesium on Formation of (OH)2-vitamin D3

Completed Last updated 11 February 2020

What this trial tests

trial testing serum value 1,25(OH)2 vitamin D in Hydroxylase Deficiency in 50,000 participants. Completed in 28 May 2019.

Timeline

1 January 2017

Primary endpoint
31 December 2018

28 May 2019

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50,000
Start date	1 January 2017
Primary completion	31 December 2018
Estimated completion	28 May 2019

Drugs / interventions tested

serum value 1,25(OH)2 vitamin D

Conditions studied

Hydroxylase Deficiency — all drugs for Hydroxylase Deficiency →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Eligibility, any sex, with Hydroxylase Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective database analysis. The target values are the serum values of 25(OH)D, of 1,25(OH)2D, of magnesium and creatinine as well as age and sex of the patients. The laboratory values of the years 2017 and 2018 are included. There are no additional measurements on patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04237480 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 11 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04237480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing